Background--We aim to generate a line of "universal donor" human induced pluripotent stem cells (hiPSCs) that are nonimmunogenic and, therefore, can be used to derive cell products suitable for allogeneic transplantation.
I
nduced pluripotent stem cells (iPSCs) are among the most promising therapeutics for regenerative myocardial therapy because they can be differentiated into theoretically unlimited numbers and types of cells. Multiple lineages of iPSC-derived cardiac cells have been administered via direct intramyocardial injection 1, 2 or as a patch of engineered tissue, 3, 4 but the effectiveness of these approaches has been limited by a variety of factors, [5] [6] [7] including, perhaps most important, the exceptionally small proportion of cells that are engrafted by the native tissues at the site of administration. Because these experiments are generally performed with allogeneic or xenogeneic cells, the low engraftment rate may be at least partially attributable to the host animal's immune response. Immunogenicity is expected to be less of a problem in clinical practice because human iPSCs (hiPSCs) can be generated from each individual patient's own somatic cells.
However, when iPSCs were generated from a line of inbred (C57BL/6) mice and transplanted back into adult mice of the same inbred strain, most of the tumors formed from the transplanted iPSCs were immune rejected, regardless of whether the iPSCs were generated via the standard retroviral reprogramming method or a more novel episomal approach that did not alter the cellular genome. Subsequent analyses found evidence of necrosis and T-cell infiltration, which the authors attributed to the abnormal expression of minor antigens. 9 Thus, the potential immunogenicity of autologous hiPSC-derived cardiac cells continue to be one of the barriers to their clinical use. Immune rejection is mediated by molecules in major histocompatibility classes (MHCs) I and II, which, in humans, are encoded by the human leukocyte antigen system (HLAI and HLAII, respectively). MHC-I proteins form a complex with b 2 microglobulin (B2M) on the cell surface, where they are recognized and destroyed by T cells; thus, several studies [10] [11] [12] [13] [14] have been conducted to determine whether the immunogenicity of hiPSCs can be reduced by disrupting the expression of B2M. As expected, the B2M-deficient hiPSCs were not recognized by T cells, but they remained susceptible to elimination via the "missing self" response, which is mediated by natural killer (NK) cells. Furthermore, human endothelial cells can activate alloantigen reactive memory CD4 + T cells, which may explain why cell-mediated rejection of vascularized human allografts can occur even after professional antigenpresenting cells are depleted. However, the endothelial cellinduced activation of reactive memory T cells requires the expression of MHC-II molecules, 15 and when both alleles of the class II MHC transactivator (CIITA) gene were knocked out in human endothelial cells, the cells did not elicit an immune response after transplantation into mice. 16 This report presents results of studies that were conducted to determine whether the immunogenicity of hiPSC-derived cells could be reduced, or even eliminated, by knocking out the expression of both B2M and CIITA. The knockout mutations were induced in hiPSCs via CRISPR/Cas9 gene editing, and both wildtype (WT) and B2M/CIITA double-knockout (HLAI/II knockout) hiPSCs were differentiated into cardiomyocytes. Our results confirmed that the HLAI/II knockout mutation did not alter the expression of pluripotency genes in hiPSCs or the electrical properties of hiPSC-derived cardiomyocyte spheroids; however, measures of T-cell activation were 3-fold higher when human peripheral blood mononuclear cells (PBMCs) were incubated with WT hiPSC-derived cardiomyocytes rather than HLAI/II knockout hiPSC-derived cardiomyocytes, and spheroids of HLAI/II knockout hiPSC-derived cardiomyocytes were more resistant than WT hiPSC-derived cardiomyocyte spheroids to the activity of CD8 + T cells and CD4 + immune cells.
Methods
The data, analytical methods, and study materials are available to other researchers for the purposes of reproducing the results or replicating the procedure, as described in this article or on contacting the corresponding author. What Are the Clinical Implications?
• Human leukocyte antigen I/II knockout human induced pluripotent stem cell-derived cells may be less susceptible to immune rejection when administered to patients.
virus-containing supernatants were collected 48 hours after transfection and centrifuged at 15009g and 4°C for 10 minutes to pellet the cell debris; then, the supernatants were filtered through a 0.45-lm low-protein-binding membrane (Millipore) and used immediately to transduce the hiPSCs. After transduction, the hiPSCs were expanded on Matrigel-coated dishes for 4 days with puromycin (5 lg/mL) selection, and individual puromycin-resistant single-cell-derived colonies were harvested and expanded in culture. B2M and CIITA knockouts were verified via Sanger sequencing and Western blot analysis.
Generation of hiPSC-Derived Cardiomyocyte Spheroid Fusions
Spheroid fusion was performed, as previously described. 17 Briefly, spheroids were grown for 7 days, and then 2 spheroids of diameter 800 lm were placed in a 2-mL, round-bottom test tube to ensure that the spheroids were in physical contact. Spheroids were cultured in maintenance medium and spontaneous beating was typically observed within 1 day of fusion; the fusions contracted into small, compact, tissuelike structures by day 7. 
Optical Mapping of V m and Ca

2+
Optical mapping of spheroids was performed, as described previously. 17 Briefly, spheroids were double stained with a low-affinity Ca 2+ -sensitive dye (Cal-520FF, 10 lmol/L for 1 hour) 18 and a transmembrane voltage (V m )-sensitive dye (RH-237, 2.5 lmol/L for 5 minutes), held in place with 2 nylon meshes (280-lm pore), and perfused with Hank's balanced salt solution (36°C-37°C) supplemented with 10 lmol/L of blebbistatin to eliminate motion artifacts caused by spheroid contractions. Spheroids were stimulated with 2-ms rectangular pulses delivered from a bipolar electrode placed near the edge of the spheroid, and action potentials (APs) and Ca 2+ transients (CaTs) were recorded with a 16916 photodiode array (Hamamatsu) at a spatial resolution of 110 lm per diode. 19 Activation times were measured at 50% of the AP amplitude and used to construct isochronal maps of activation spread. Conduction velocity was calculated at each recording site from local activation times and averaged across the whole map. AP and CaT durations were measured at 50% of signal recovery.
PBMC Isolation
Human whole blood was collected into BD Vacutainer sodium heparin tubes, Figure 1 . continued incubated at 37°C in 5% CO 2 and humidified air. Spheroids were observed at day 3 and day 5 for gross morphologic changes. 
T-Cell Activation
Results
CRISPR/Cas9-Mediated HLAI/II-Knockout hiPSCs carrying knockout mutations for both HLA class I and class II (HLAI/II knockout hiPSCs) were generated via CRISPR/Cas9 gene editing technology with guide RNA sequences flanking B2M ( Figure 1A ) and CIITA ( Figure 1C ). After editing, the B2M gene contained a 4-bp insertion, a 14-bp deletion, and a 10-bp deletion, and the CIITA gene contained a 1-bp insertion ( Figure 1B and 1D and Figures S1 and S2), which introduced new stop codons that prematurely terminated the translation of both genes ( Figure 1F and 1H). Successful knockout was confirmed via Western blot analysis ( Figure 1E and 1G) and immunofluorescent staining 
HLAI/II Knockout Did Not Alter the Differentiation of hiPSC-Derived Cardiomyocytes or the Electrophysiological Parameters of hiPSC-Derived Cardiomyocyte Fusions
WT and HLAI/II knockout hiPSCs were differentiated into cardiomyocytes via an established protocol. 17 Spontaneously contracting cells typically appeared 8 to 10 days after Figure 2 . Generation and characterization of pluripotency, telomerase activity, and differentiation of human cardiac lineage-induced pluripotent stem cells (hiPSCs) in cardiomyocytes, endothelial cells (ECs), and spheroid-derived cardiomyocytes from wild-type (WT) and hiPSC-derived human leukocyte antigen (HLA) I/II knockout cells. A, hiPSC-derived WT and hiPSC-HLAI/II knockout cells were cultured on glass coverslips and were immunolabeled for pluripotent markers octamer-binding transcription factor 4 (Oct4), Nanog homeobox (Nanog), tumour rejection antigen (Tra-1-60), and stage-specific embryonic antigen-4 (SSEA4) counterstained with 4',6-diamidino-2-phenylindole (DAPI) staining for nuclei. B, hiPSC-derived WT and hiPSC-derived HLAI/II knockout were cultured for 50 passages, and passages 1, 20, and 50 were collected. (i) telomerase activity was evaluated with a nondenaturing polyacrylamide gel and (ii) quantified at the indicated time points via densitometry analysis. C&D, WT and knockout hiPSC-derived cardiomyocytes stained for human cardiac troponin T (hcTnT; red), phalloidin (green), and NK2 homeobox 5 (NKX2.5) (gray); counterstained nuclei with DAPI and WT and knockout hiPSC-derived ECs stained for wheat germ agglutinin (WGA; red) CD144 (gray); and counterstained nuclei with DAPI. E&F, WT and knockout hiPSC-derived cardiomyocytes stained for b2 microglobulin (B2M; green) and phalloidin (red) and counterstained nuclei with DAPI and WT, and knockout hiPSC-derived ECs stained for class II major histocompatibility class transactivator (CIITA; green) and CD31 (red) and counterstained nuclei with DAPI. H&G, hiPSC-derived WT and hiPSCderived HLAI/II knockout differentiated cardiomyocytes were cultured on glass coverslips and were immunolabeled for cardiomyocyte marker proteins myosin light chain 2 (MLC2v), hcTnT, phalloidin, and connexin 43 (Cx43); nuclei were counterstained with DAPI markers.
differentiation was initiated, and cardiomyocyte identity was confirmed via immunofluorescent assessments of the expression of cardiomyocyte markers, such as ventricular myosin light chain 2, cardiac troponin T, phalloidin, and connexin 43 ( Figure 2C , 2D, 2G & 2H). Furthermore, when spheroids composed of WT or HLAI/II hiPSC-derived cardiomyocytes Figure 2 . continued were fused, the fusions contracted spontaneously and synchronously within 7 days of the fusion event, and electron micrographs confirmed that the HLAI/II knockout spheroids were structurally normal, with well-defined sarcomeres and Zlines ( Figure 3C , 3E & 3F). Optical maps of action-potential propagation and traces of individual APs and CaTs ( Figure 3A and 3B) indicated that cardiomyocytes were electrically coupled both within and between the fused spheroids with no detectable conduction delay at the interspheroid boundary and that measurements of conduction velocity, the durations of both APs (AP duration measured at 50% of signal recovery) and CaTs (CaT measured at 50% of signal recovery), and CaT increase times in WT and HLAI/II knockout spheroids were not statistically different ( Figure 3D and 3G).
HLAI/II Knockout Reduces the Immunogenicity of hiPSC-Derived and Spheroid Cardiomyocytes
The immunogenicity of HLAI/II knockout and WT hiPSCderived cardiomyocytes were compared by first culturing monolayers of the cells with allogeneic human PBMCs, then afterward collecting the PBMCs for antibody staining (Table S1 ) against the T-cell marker CD3 and the T-cell activation marker CD69 ( Figure 4A ). Assessments were also performed in PBMCs that had been cultured in the absence of hiPSC-derived cardiomyocytes (negative control) and in PBMCs that had been cultured without hiPSC-derived cardiomyocytes but with the T-cell-activator phorbol 12-myristate 13-acetate (positive control). The proportion of T cells that were activated by WT hiPSC-derived cardiomyocytes (>75%) ( Figure 4B ) was 3-fold greater than the proportion that was activated by HLAI/II knockout hiPSC-derived cardiomyocytes (<25%), and the extent of T-cell activation by HLAI/II knockout hiPSC-derived cardiomyocytes was similar to the extent observed in the negative control (21%) (Figure 4 and 4C). Furthermore, when WT spheroids were cocultured with human PBMCs for 5 days, WT cardiomyocyte spheroids were significantly reduced in size compared with the knockout cardiomyocyte spheroids, and the contractions of the WT cardiomyocyte spheroids were visibly less forceful than those of the knockout cardiomyocyte spheroids (Videos S1 through S4). Similar results were observed in 3-day coculture experiments with purified human CD4 + and CD8 + T cells (Figure 4D) . Consistent with these data, T-cell activation markers were significantly elevated in coculture experiments with WT spheroids but not with HLAI/II knockout spheroids. Last, HLA-G is known to inhibit NK cell recognition and the killing of cells that lack other HLAs. Expression of HLA-E and HLA-F A, hiPSC-derived WT cells were differentiated cardiomyocytes that generated spheroid fusion (i) at 7 days of culture to generate (ii) optical maps of action potential propagation, and (iii) traces of individual action potentials (blue) and calcium transients (red); the number of each trace in ii corresponds to the location identified in the map shown in i. B, Conduction velocity. The durations of the action potentials (C) and calcium transients (D) at 50% (ie, APD 50 and CaTD 50 , respectively) and CaT increase time recovery (E) were determined for fusions of 2 large spheroids after 7 days in culture (WT, blue) and (HLAI/II knockout, green). F, hiPSC-derived HLAI/II knockout cells were differentiated cardiomyocytes that generated spheroid fusion (i) at 7 days of culture to generate (ii) optical maps of action potential propagation, and (iii) traces of individual action potentials (blue) and CaTs (red); the number of each trace in ii corresponds to the location identified in the map shown in i. G, The ultrastructure of the spheroid fusion was analyzed by transmission electron microscope to identify sarcomere, Z-lines, mitochondria, and endoplasmic reticulum (ER). AT indicates activation time; B2M, b 2 microglobulin; CV, conduction velocity.
was inhibited in HLAI/II knockout cardiomyocyte spheroids after coculture with human PBMCs, but HLA-G expression was not inhibited. These results are consistent with the essential role of CIITA in transcriptional activation of HLA-E and HLA-F genes, but not the HLA-G gene. 20 Although
Western blot analysis indicated that interferon-c did not induce the NK-cell inhibitory ligands HLA-E and HLA-F in HLAI/II knockout hiPSC-derived cardiomyocytes, the expression of HLA-G, which protects placental trophoblasts from lysis by maternal NK cells, 20 was unchanged ( Figure 4E ). show that WT cardiomyocyte spheroids challenged with immune cells were smaller compared with the knockout cardiomyocyte spheroids; in addition, the contractions of the WT cardiomyocyte spheroids were visibly less forceful than those of the knockout cardiomyocyte spheroids. i) spheroids without immune cells denoted "control", ii) spheroids co-cultured with CD8+ cells for 3 days denoted "CD8+: day3", iii) spheroids co-cultured with CD4+ cells for 3 days denoted "CD4+: day3" iv) spheroids cocultured with PBMC cells for 3 days denoted "PBMC: day3" and v) spheroids co-cultured with PBMC cells for 3 days denoted "PBMC: day5". E, Western blot data for the following: lane 1, WT cardiomyocytes; lane 2, WT cardiomyocytes treated with interferon-c; lane 3, knockout cardiomyocytes; and lane 4, knockout cardiomyocytes treated with interferon-c for HLA class I histocompatibility antigen, a chain (HLA-E, HLA alpha chain E; HLA-F, HLA alpha chain F; HLA-G, HLA alpha chain G). Iso indicates CD69 isotype control; PE-A, phycoerythrin channel of flow cytometer.
ORIGINAL RESEARCH
Discussion
hiPSCs are not expected to provoke an immune response during clinical use because they can be generated from the somatic cells of each individual patient. 8 Nevertheless, studies suggest that the tumors formed from transplanted murine iPSCs can be rejected by the recipient mice, even if the cells and the mice are genetically identical. 9 Furthermore, the time required to produce autologous hiPSC-derived cells precludes their use for treatment of acute conditions. Thus, techniques for generating nonimmunogenic hiPSCs could be used to increase the engrafted cells and to produce lines of allogeneic "universal donor" hiPSCs. Herein, we show that the CRISPR/Cas9 gene-editing system can successfully knock out 2 key components (B2M and CIITA) of the HLAI/II system in hiPSCs without altering the cells' pluripotency or telomerase activity, that HLAI/II knockout hiPSC-derived cardiomyocytes fail to activate human T cells, and those spheroids of HLAI/II knockout hiPSC-derived cardiomyocytes retain the electrical properties of WT hiPSC-derived cardiomyocyte spheroids but are more resistant to the cytotoxic effects of PBMCs. When biallelic CIITA-knockout mutations were induced in untransformed endothelial cells, 16 the CIITA-knockout cells failed to activate alloreactive CD4 + memory T cells, and their immunogenicity was restored via the overexpression of CIITA, which confirmed that the observed phenotype was attributable to the loss of CIITA, rather than random off-target mutations. CIITA has also been linked to the induction of HLA-E and HLA-F, but does not appear to activate the expression of HLA-G. 21 Notably, although the outermost layer of the human placenta is generally devoid of most HLAI/II molecules, and, consequently, escapes recognition from maternal T cells, HLA-G is expressed by trophoblast cells that are in direct contact with maternal tissues, where it appears to inactivate NK cells by functioning as a "self" antigen. 20 The presence of HLA-E on the cellular surface also protects against lysis by NK cells because it binds to the NK-cell inhibitory complex CD94/Natural killer group 2, member A (NGK2A). [22] [23] [24] Also, human embryonic stem cells in which the B2M gene had been knocked out and replaced with HLA-E were not recognized as allogeneic by CD8 + T cells, failed to bind anti-HLA antibodies, and resisted the cytotoxic activity of NK cells. 25 In conclusion, the results presented in this report demonstrate that the CRISPR/Cas9-mediated knockout of B2M and CIITA, which are crucial for the display of HLAI/II proteins at the cellular surface, does not alter the pluripotency of hiPSCs or the electrophysiological properties of spheroids composed of HLAI/ II knockout hiPSC-derived cardiomyocytes. However, the HLA knockout hiPSC-derived cardiomyocytes did not activate T cells, as measured by expression of CD69, which is known to be upregulated in acutely activated T cells responding to antigen, and were more resistant than WT hiPSC-derived cardiomyocytes to the cytotoxic effects of PBMCs, including NK cells. Thus, cells derived from HLAI/II knockout hiPSCs may be less susceptible to immune rejection when administered to patients and, therefore, provide a source of universal donor cells to be used for the treatment of acute conditions.
